e12525#Background:Breast cancer is a frequent and heterogeneous disease where several clinical, histological and molecular factors determine its prognosis. Our objective is to estimate the prognostic factors influencing overall survival (OS) in patients with breast cancer.Methods:We conducted our first ...
SAN ANTONIO — Overall survival and, more intriguingly, breast cancer–specific survival are significantly enhanced by statin therapy when used both in the prediagnostic and the postdiagnostic setting compared with no statin use, suggests a Swedish nationwide study reported here at the San Antonio Br...
[5] Finn, R. S. et al. Overall Survival (OS) With First-Line Palbociclib Plus Letrozole (PAL+LET) Versus Placebo Plus Letrozole (PBO+LET) in Women With Estrogen Receptor-Positive/Human Epidermal Growth Factor Recept...
“Based on the results of our study, women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit,” Khan, the Bluhm Family Professor of Cancer Research...
The overall 5-year relative survival rate for breast cancer is 91.2%. This means that about 91 out of 100 people are alive 5 years after they’ve been diagnosed with breast cancer. The 10-year breast cancer relative survival rate is 84% (84 out of 100 people are alive after 10 years)...
Breast cancer is the most prevalent kind of cancer among women and there is a need for a reliable algorithm to predict its prognosis. Previous studies focused on using gene expression data to build predictive models. However, recent advancements have made multi-omics cancer data sets (gene expres...
[4] Azim H, Partridge A. Biology of breast cancer in young women. Breast Cancer Res. 2014; 16: 427. [5] Seock-Ah Im, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019; 381(4): 307-316. ...
overall survival (OS), distant recurrence-free survival (DRFS), and pathologic complete response (pCR) in breast cancer, where OS is defined as time from initial diagnosis to death from any cause, DRFS is defined as time from diagnosis to distant recurrence, death from cancer, or death from...
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. ...
Adjuvant radiotherapy (RT) in breast cancer (BC) is often used to eradicate remaining tumor cells following surgery with the goal of maximizing local control and increasing overall survival. The current study investigated the impact of age and BC molecul